GEP20227431B - Composition for eradicating helicobacter pylori - Google Patents

Composition for eradicating helicobacter pylori

Info

Publication number
GEP20227431B
GEP20227431B GEAP201915593A GEAP2019015593A GEP20227431B GE P20227431 B GEP20227431 B GE P20227431B GE AP201915593 A GEAP201915593 A GE AP201915593A GE AP2019015593 A GEAP2019015593 A GE AP2019015593A GE P20227431 B GEP20227431 B GE P20227431B
Authority
GE
Georgia
Prior art keywords
composition
helicobacter pylori
eradicating helicobacter
eradicating
pylori
Prior art date
Application number
GEAP201915593A
Other languages
English (en)
Inventor
Haneul Jeong
Yu-Gyeong Park
Jae Min Kim
Naree Shin
Eun Kyung Kim
Shin-Young Riu
Geun Seog Song
Ahrong Kim
Kyeongmin Oh
Ji Won Lee
Eun Ji Kim
Dongkyu Kim
Bog Tae Kim
Hyun Ji Kang
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of GEP20227431B publication Critical patent/GEP20227431B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GEAP201915593A 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori GEP20227431B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (1)

Publication Number Publication Date
GEP20227431B true GEP20227431B (en) 2022-10-25

Family

ID=69643254

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201915593A GEP20227431B (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori
GEAP202215593A GEAP202215593A (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202215593A GEAP202215593A (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Country Status (28)

Country Link
US (2) US20210196685A1 (enExample)
EP (1) EP3843723B1 (enExample)
JP (1) JP7189327B2 (enExample)
KR (1) KR20200026118A (enExample)
CN (1) CN112638378A (enExample)
AR (1) AR116026A1 (enExample)
AU (1) AU2019328903B2 (enExample)
CA (1) CA3107624C (enExample)
DK (1) DK3843723T3 (enExample)
EA (1) EA202190622A1 (enExample)
ES (1) ES3060114T3 (enExample)
FI (1) FI3843723T3 (enExample)
GE (2) GEP20227431B (enExample)
HR (1) HRP20260170T1 (enExample)
JO (1) JOP20190201B1 (enExample)
LT (1) LT3843723T (enExample)
MX (1) MX2021002278A (enExample)
MY (1) MY195494A (enExample)
PH (1) PH12021550385A1 (enExample)
PL (1) PL3843723T3 (enExample)
PT (1) PT3843723T (enExample)
RS (1) RS67791B1 (enExample)
SG (1) SG11202101920WA (enExample)
SI (1) SI3843723T1 (enExample)
SM (1) SMT202600153T1 (enExample)
UA (1) UA126993C2 (enExample)
UY (1) UY38348A (enExample)
WO (1) WO2020045992A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
MA41730B1 (fr) * 2015-06-08 2019-03-29 Cj Healthcare Corp Utilisation de dérivé de benzimidazole pour l'acidité nocturne
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
JP2021535910A (ja) 2021-12-23
JP7189327B2 (ja) 2022-12-13
KR20200026118A (ko) 2020-03-10
US20210196685A1 (en) 2021-07-01
JOP20190201A1 (ar) 2020-02-29
UY38348A (es) 2020-03-31
EP3843723A1 (en) 2021-07-07
WO2020045992A1 (en) 2020-03-05
CA3107624A1 (en) 2020-03-05
BR112021003578A2 (pt) 2021-05-18
AR116026A1 (es) 2021-03-25
MX2021002278A (es) 2021-08-11
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
LT3843723T (lt) 2026-03-25
HRP20260170T1 (hr) 2026-05-08
SI3843723T1 (sl) 2026-04-30
EP3843723A4 (en) 2022-06-29
ES3060114T3 (enExample) 2026-03-25
SMT202600153T1 (it) 2026-05-12
US20250241897A1 (en) 2025-07-31
EP3843723B1 (en) 2026-01-07
RS67791B1 (sr) 2026-03-31
JOP20190201B1 (ar) 2024-04-18
AU2019328903A1 (en) 2021-04-29
DK3843723T3 (da) 2026-02-09
PT3843723T (pt) 2026-01-27
CA3107624C (en) 2023-10-03
CN112638378A (zh) 2021-04-09
UA126993C2 (uk) 2023-03-01
AU2019328903B2 (en) 2023-01-05
PL3843723T3 (pl) 2026-06-08
PH12021550385A1 (en) 2021-09-20
MY195494A (en) 2023-01-26
AU2019328903A8 (en) 2021-05-27
FI3843723T3 (fi) 2026-02-12
SG11202101920WA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
GEAP202215593A (en) Composition for eradicating helicobacter pylori
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12020500655A1 (en) Compounds
WO2020243415A3 (en) Tead inhibitors and uses thereof
SA519402400B1 (ar) تركيبات وطرق لعلاج أمراض الهيموجلوبين
ZA202309446B (en) Rapamycin analogs and uses thereof
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018010266A (es) Métodos, dispositivos y sistemas para procesamiento de composiciones carbonosas.
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EP3870195C0 (en) NEW PROBIOTICS USEFUL TO ERADICATE HELICOBACTER PYLORI INFECTION
WO2018144870A8 (en) Compositions and methods for inhibiting reticulon 4
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
MY194673A (en) Additive for hydraulic composition
EP3886884A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF HELICOBACTER PYLORI INFECTION
MX2021002067A (es) Metodos, productos y usos relacionados con la depuracion de especies acidas de sulfuro.
MX2021001632A (es) Preparacion de una composicion que comprende un peroxido organico mediante transferencia de disolventes.
ZA202005021B (en) Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap)
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.
NZ724103A (en) Treatment of h. pylori infections using mtan inhibitors
HK40061050A (en) New probiotics useful for eradicating helicobacter pylori infection